Nucelion, a Bharat Biotech subsidiary, partnered with VeGen Bio for a new therapeutic production. The collaboration focuses on manufacturing VL-2511, a CAR-T therapy for multiple myeloma.
The focus on domestic manufacturing helps build specialized healthcare capacity in India. Lowering the cost of advanced therapies increases accessibility for patients nationwide.
Track the clinical and regulatory progress of VL-2511 through CDSCO and US FDA approvals.